CL2012003341A1 - Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. - Google Patents

Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.

Info

Publication number
CL2012003341A1
CL2012003341A1 CL2012003341A CL2012003341A CL2012003341A1 CL 2012003341 A1 CL2012003341 A1 CL 2012003341A1 CL 2012003341 A CL2012003341 A CL 2012003341A CL 2012003341 A CL2012003341 A CL 2012003341A CL 2012003341 A1 CL2012003341 A1 CL 2012003341A1
Authority
CL
Chile
Prior art keywords
bendamustine
solvate
excipient
ionic
diseases
Prior art date
Application number
CL2012003341A
Other languages
English (en)
Inventor
Jeffrey Colledge
Margaretha Olthoff
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44243599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of CL2012003341A1 publication Critical patent/CL2012003341A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica de administración oral que compende bendamustina o un éster, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofílico; combinación farmacéutica; y su uso para el tratamiento de leucemia linfocítica crónica y el mieloma múltiple, entre otras enfermedades.
CL2012003341A 2010-06-02 2012-11-29 Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. CL2012003341A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075231 2010-06-02
EP11075047 2011-03-14

Publications (1)

Publication Number Publication Date
CL2012003341A1 true CL2012003341A1 (es) 2013-06-28

Family

ID=44243599

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003341A CL2012003341A1 (es) 2010-06-02 2012-11-29 Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.

Country Status (26)

Country Link
US (2) US20130202693A1 (es)
EP (1) EP2575784B1 (es)
JP (2) JP6209446B2 (es)
KR (1) KR101830142B1 (es)
CN (1) CN103037851A (es)
AR (1) AR081835A1 (es)
AU (1) AU2011260615B2 (es)
BR (1) BR112012030654B1 (es)
CA (1) CA2800279A1 (es)
CL (1) CL2012003341A1 (es)
CO (1) CO6640318A2 (es)
DK (1) DK2575784T3 (es)
EA (1) EA031793B1 (es)
ES (1) ES2690257T3 (es)
IL (1) IL223311B (es)
JO (1) JO3587B1 (es)
MX (1) MX2012013872A (es)
MY (1) MY173873A (es)
NZ (1) NZ603872A (es)
PH (1) PH12012502281B1 (es)
PL (1) PL2575784T3 (es)
PT (1) PT2575784T (es)
SG (1) SG186099A1 (es)
TW (1) TWI500431B (es)
WO (1) WO2011151087A1 (es)
ZA (1) ZA201208823B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109157535A (zh) * 2012-02-14 2019-01-08 赛多斯有限责任公司 苯达莫司汀的制剂
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
PL2849723T3 (pl) * 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
SG11201503560TA (en) 2012-11-12 2015-06-29 Ignyta Inc Bendamustine derivatives and methods of using same
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (es) * 1903-10-08 1905-03-16
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU2002258013A1 (en) 2001-04-10 2002-10-28 Fakhreddin Jamali Animal model for evaluating analgesics
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
JP2006514119A (ja) 2003-02-12 2006-04-27 アール アンド ピー コリア カンパニー リミテッド 溶解率が向上した難溶性薬剤の溶媒系
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN101933923A (zh) 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
EP2037898A2 (en) * 2006-06-30 2009-03-25 Mcneil-PPC, Inc Ibuprofen-containing liquid filled hard capsules
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
KR100913644B1 (ko) 2007-10-09 2009-08-24 제일약품주식회사 활성성분으로 시부트라민 유리염기를 함유하는 약제학적조성물 및 그 제조방법
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2299987B1 (en) * 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter

Also Published As

Publication number Publication date
ZA201208823B (en) 2014-01-29
TW201210635A (en) 2012-03-16
AR081835A1 (es) 2012-10-24
JP2016153438A (ja) 2016-08-25
PT2575784T (pt) 2018-10-26
EP2575784B1 (en) 2018-08-08
IL223311B (en) 2018-04-30
EA031793B1 (ru) 2019-02-28
DK2575784T3 (en) 2018-10-15
US10993933B2 (en) 2021-05-04
JO3587B1 (ar) 2020-07-05
ES2690257T3 (es) 2018-11-20
MX2012013872A (es) 2013-04-03
BR112012030654A2 (pt) 2016-08-16
PL2575784T3 (pl) 2019-03-29
MY173873A (en) 2020-02-25
AU2011260615B2 (en) 2016-11-17
CN103037851A (zh) 2013-04-10
PH12012502281A1 (en) 2013-02-11
US20130202693A1 (en) 2013-08-08
AU2011260615A1 (en) 2013-01-10
IL223311A0 (en) 2013-02-03
PH12012502281B1 (en) 2017-10-20
EP2575784A1 (en) 2013-04-10
WO2011151087A1 (en) 2011-12-08
CO6640318A2 (es) 2013-03-22
EA201291104A1 (ru) 2013-06-28
JP6373300B2 (ja) 2018-08-15
CA2800279A1 (en) 2011-12-08
BR112012030654B1 (pt) 2021-11-09
NZ603872A (en) 2014-07-25
US20150374670A1 (en) 2015-12-31
JP2013527207A (ja) 2013-06-27
TWI500431B (zh) 2015-09-21
JP6209446B2 (ja) 2017-10-04
KR101830142B1 (ko) 2018-02-20
SG186099A1 (en) 2013-01-30
KR20130086157A (ko) 2013-07-31

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX375417B (es) Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
PE20140255A1 (es) Tableta dispersable en forma oral
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
GT201400111A (es) Triazolopiridinas sustituidas
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
MX2016001480A (es) Formulacion de inhibidores de syk.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.